MIRAMAR, Fla., July 26, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) subsidiary Olaregen Therapeutix announced in May that the company has executed a Distribution Agreement with Nexgen Medical Sdn Bhd, Inc. (“Nexgen”) to be Generex’s exclusive distributor to import, market and sell the Excellagen line of wound care products in Malaysia pending their Ministry of Health’s approval. We are pleased to announce that Nexgen did, in fact, receive...
NuGenHealth Software as a Service (SaaS) platform that enables their clients to monitor the health and wellbeing of their patient population. Westside Medicine & Cardiology, Inc. is a professional corporation that engages medical providers who are duly licensed in Ohio to provide primary care, cardiology, and RPM services. MIRAMAR, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and...
Update on Ii-Key-SARS-CoV-2 vaccine program Appointment of Dr. Craig Eagle to be Chairman of the Board of NuGenerex Immuno-Oncology Inc. pending board approval. Re-Launch of Excellagen® in the VA Hospital Network Launch of Remote Patient Monitoring (RPM) Business NuGenHealth Update on Partnership & Anticipated Acquisition of AltuCell MIRAMAR, Fla., May 10, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) (“Generex” or the “Company”), an...
NuGenHealth Software as a Service (SaaS) platform that enables their clients to monitor the health and wellbeing of their patient population. Florida Health Care Associates is a professional corporation that engages medical providers who are duly licensed in Florida to provide primary care and RPM services (http://www.floridahealthcareassociates.com/home.htm) MIRAMAR, Fla., May 06, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the...
MIRAMAR, Fla., May 05, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative “Complete Vaccine” to fight SARS-CoV-2, today provided guidance on the terms of its agreement with Beijing Youfeng Biological Technology, Ltd (Youfeng-BI) in connection with the $2,000,000...
MIRAMAR, Fla., May 04, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative “Complete Vaccine” to fight SARS-CoV-2, today announced the call in details and an updated agenda for the shareholder conference call on Thursday May 6, 2021 at 9:00 AM. Due to a significant...
MIRAMAR, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) subsidiary Olaregen Therapeutix today announced that the company has executed a Distribution Agreement with Nexgen Medical Sdn Bhd, Inc. (“Nexgen”) to be Generex’s exclusive distributor to import, market and sell the Excellagen line of wound care products in Malaysia. Nexgen is coordinating the approval of Excellagen with the Malaysian Ministry of Health and expects commercial...
Generex receives $2 million payment from Chinese partners to provide research results, data, and necessary documents to support an IND submission to the Chinese National Medical Products Administration (NMPA) MIRAMAR, Fla., April 27, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) today announced that in connection with its partnership with the National Institute for Viral Disease Control and Prevention,...
Response to Pre-IND Comments Pre-clinical and ex-vivo results GMP Manufacturing Adjuvant data Revised protocol as per FDA recommendations MIRAMAR, Fla., April 12, 2021 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO – www.nugenerexio.com), a subsidiary of Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development...
NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- Last Chance for Children’s (LCFC) Mission is to help save children’s lives anywhere in the world. Due to the COVID-19 pandemic we are now focusing our efforts to help eradicate this virus so we could safely and effectively vaccinate children in need. Why do we need a COVID-19 Vaccine for Children and Pregnant Women? Children’s lives have been completely disrupted by the coronavirus pandemic. To date, none of the vaccines against COVID-19 are...
MIRAMAR, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB: GNBT) (“Generex or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative “Complete Vaccine” to fight SARS-CoV-2, today announced that it will hold a shareholder conference call on Thursday May 6, 2021 at 9:00 AM ET. On this upcoming conference call, Generex President and Chief...
Ii-Key-SARS-CoV-2 vaccine generates vaccine-specific antibodies and T cell responses in a transgenic mouse model The Ii-Key vaccine elicits both CD4+ T Helper cell (Th1) and CD8+ responses that are necessary for long-term immune memory Initiated discussions with a major research institution on licensing therapeutic antibodies against SARS-CoV-2 MIRAMAR, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) (...
The access information for the investor conference call is as follows: Domestic US/Canada - 1-(866) 342-8588 Direct Toll / International - 1-(203) 518-9865 Program Title: Generex Biotechnology Conference Call Conference ID – 61174 Agenda Update on Ii-Key-SARS-CoV-2 vaccine program China Licensing & Research Agreement advances with $100,000 payment guarantee and $1 million advance on development funding Licensing opportunity for COVID-19 therapeutic antibodies MIRAMAR, Fla., Feb. 03, 2021...
MIRAMAR, Fla., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) today announced that it will hold an investor conference call on Friday February 5, 2021 at 9:00 AM. Joseph Moscato, Generex President & Chief Executive Officer stated: “I am excited to give our first shareholder conference call to update investors about the development of our Ii-Key complete vaccine against the SARS-CoV-2 coronavirus that continues to ravage the world. We have...
The trademark application can be found at USPTO.gov by searching “Complete Vaccine” in the Trademark Electronic Search System (TESS) Ii-Key-SARS-CoV-2 vaccine enters GMP production for clinical supply Ii-Key epitopes selected that elicit both CD4+ T Helper cell (Th1) and CD8+ responses that are necessary for long-term immune memory Ii-Key epitopes elicited no Th2 T cell responses that have been linked to antibody dependent enhancement of disease and cytokine storm Ii-Key epitopes have been...
Memorandum of Understanding (MOU) signed by both parties Negotiating final contract terms Upfront payment on closing Licensing fees, expenses, and price per dose to be determined Bintai Kinden Corporation Berhad ( www.bintai.com.my ) is an investment holding company headquartered in Malaysia with operations throughout South-East Asia, China, and the Arabian Gulf Region An 8K on the MOU will be filed today MIRAMAR, Fla., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (...
$2.5 million upfront for the Ii-Key-H1 vaccine from NuGenerex-Immuno-Oncology (NGIO) and to initiate epitope identification for Ii-Key vaccine development against the emerging swine flu in China G4EA H1N1 100% funding for manufacturing, development and commercial registration and approval of an Ii-Key-H1 vaccine in China Plans to incorporate Ii-Key-H1 vaccine into universal seasonal influenza vaccine An 8K will be filed on the contract today MIRAMAR, Fla., Nov. 19, 2020 (GLOBE NEWSWIRE) --...
$50 million licensing deal for the Ii-Key platform to develop vaccines for infectious diseases and cancer Deal includes first contract for Ii-Key- SARS-CoV-2 vaccine against COVID-19 in China with a $5 million upfront licensing fee, 100% funding for manufacturing, development and commercial registration and a $20 million success fee for approval Ii-Key- SARS-CoV-2 vaccine in China Royalty payments for COVID vaccine with billion-dollar royalty potential Framework agreement for the development of...
MIRAMAR, Fla., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) today announced that Richard Purcell, Executive Vice President of Research & Development at Generex and NuGenerex Immuno-Oncology will be featured on the Yo! Dr. Yo Show to provide an update on the company’s COVID-19 vaccine development program. The interview will be live streamed at 2:00 PM on Friday, November 13, 2020 at can be heard at the following link: https://streamyard.com/6pykxvt9m4 The Yo!...
